| NCT07156136 | Study of IMC-P115C in Advanced PRAME-Positive Cancers | RECRUITING | PHASE1 | 2024-11-07 | 2029-08-30 | 2027-09-30 |
| NCT06112314 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | RECRUITING | PHASE3 | 2024-06-05 | 2027-10-16 | 2027-10-16 |
| NCT06840119 | Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | RECRUITING | PHASE1, PHASE2 | 2024-01-10 | 2027-11-30 | 2026-11-30 |
| NCT05549297 | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | RECRUITING | PHASE3 | 2022-12-19 | 2028-07 | 2028-03 |
| NCT05867056 | Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection | WITHDRAWN | PHASE1 | 2020-08-12 | 2024-12-15 | 2024-09-10 |
| NCT04262466 | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | RECRUITING | PHASE1, PHASE2 | 2020-02-25 | 2026-08 | 2026-02 |
| NCT03973333 | Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab | WITHDRAWN | PHASE1, PHASE2 | 2019-05-17 | 2023-09-25 | 2023-09-25 |
| NCT03515551 | Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers | TERMINATED | PHASE1, PHASE2 | 2018-06-15 | 2021-05-10 | 2021-05-10 |
| NCT03070392 | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | ACTIVE_NOT_RECRUITING | PHASE2 | 2017-10-16 | 2025-12 | 2020-10-13 |
| NCT02889861 | IMCgp100-401 Rollover Study | TERMINATED | PHASE2 | 2017-01-11 | 2019-04-22 | 2019-04-22 |
| NCT02570308 | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma | COMPLETED | PHASE1, PHASE2 | 2016-02-29 | 2022-10-17 | 2020-03-20 |
| NCT02535078 | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | WITHDRAWN | PHASE1, PHASE2 | 2015-11 | 2023-09-06 | 2023-06-19 |
| NCT01211262 | Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma | COMPLETED | PHASE1 | 2010-09-28 | 2017-02-16 | 2016-02-16 |